What to Watch in Gynecologic Cancer (Markman/ASCO)

medscape
 June 01, 2016
 

• Overall Survival With Olaparib in Ovarian Cancer

• Hormonal Maintenance Therapy After Platinum Chemotherapy in Ovarian Cancer

• Prolonging the Platinum-Free Interval in Ovarian Cancer

 

References

1. Ledermann JA, Harter P, Gourley C, et al. Overall survival (OS) in patients (pts) with platinum-sensitive relapsed serous ovarian cancer (PSR SOC) receiving olaparib maintenance monotherapy: An interim analysis. Program and abstracts of the American Society of Clinical Oncology Annual Meeting; June 3-7, 2016; Chicago, Illinois. Abstract 5501.
2. Ledermann JA, Harter P, Gourley C, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med. 2012;366:1382-1392. Abstract
3. Gershenson DM, Bodurka DC, Coleman RL, et al. Hormonal maintenance therapy for women with low grade serous carcinoma of the ovary or peritoneum. Program and abstracts of the American Society of Clinical Oncology Annual Meeting; June 3-7, 2016; Chicago, Illinois. Abstract 5502.
4. Frenel JS, Le Tourneau C, O'Neil BH, et al. Pembrolizumab in patients with advanced cervical squamous cell cancer: Preliminary results from the phase Ib KEYNOTE-028 study. Program and abstracts of the American Society of Clinical Oncology Annual Meeting; June 3-7, 2016; Chicago, Illinois. Abstract 5515.
5. Pignata S, Scambia G, Raspagliesi F, et al. The MITO8 phase III international multicenter randomized study testing the effect on survival of prolonging platinum-free interval (PFI) in patients with ovarian cancer (OC) recurring between 6 and 12 months after previous platinum-based chemotherapy: A collaboration of MITO, MANGO, AGO, BGOG, ENGOT, and GCIG. Program and abstracts of the American Society of Clinical Oncology Annual Meeting; June 3-7, 2016; Chicago, Illinois. Abstract 5505.